Dapagliflozin 10 mg clinical trials

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

This study is testing if a drug called dapagliflozin can help slow down kidney damage in people with a genetic kidney condition called Polycystic Kidney Disease (ADPKD). It compares the drug to a dummy pill (placebo) to see if it improves kidney function.